A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy…
More: continued here
Filed under: Gout on January 9th, 2012 | No Comments »
According to a phase II clinical trial, the drug rilonacept, which inhibits the protein interleukin-1 (IL-1), substantially reduces acute gout flares that occur at the start of uric acid-reducing therapy and is noted to be generally well tolerated with no serious infections or serious adverse events occurring in relation to the treatment…
More: continued here […]
Filed under: Gout on January 7th, 2012 | No Comments »
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy…
More: continued here
Filed under: Gout on November 26th, 2011 | No Comments »
Results from a new pharmacokinetic (PK) study presented at the annual meeting of the American College of Rheumatology (ACR) provide new evidence-based guidance for healthcare providers on using colchicine for gout flare prophylaxis in the presence of renal impairment…
More: continued here
Filed under: Gout on November 10th, 2011 | No Comments »
X-ray images known as CT scans can help confirm gout in patients who are suspected of having the painful condition but receive negative results from traditional tests, a Mayo Clinic study has found. The type of CT scan analyzed, dual-energy computed tomography, is also valuable for diagnosing people who cannot be tested with the typical […]
Filed under: Gout on November 7th, 2011 | No Comments »
New research shows that use of poor footwear is common among patients with gout. According to the study published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), gout patients who make poor footwear choices experienced higher foot-related pain, impairment and disability…
More: continued here
Filed under: Gout on October 4th, 2011 | No Comments »
Individuals with severe, chronic gout who have not responded to conventional treatment may benefit from six-months’ worth of pegloticase treatment. Researchers from Duke University Medical Center, Durham, N.C., reported in JAMA (Journal of the American Medical Association) that individuals experienced better levels of uric acid as well as physical function, quality of life, and less […]
Filed under: Gout on August 17th, 2011 | No Comments »
Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA…
More: continued here
Filed under: Gout on August 17th, 2011 | No Comments »
A new study shows the prevalence of gout in the U.S. has risen over the last twenty years and now affects 8.3 million (4%) Americans. Prevalence of increased uric acid levels (hyperuricemia) also rose, affecting 43.3 million (21%) adults in the U.S…
More: continued here
Filed under: Gout on July 31st, 2011 | No Comments »
Health professionals should ensure they are prescribing correct doses of colchicine, a treatment for acute gout, after three elderly patients were hospitalised within a fortnight, doctors at St Vincent’s Hospital in Sydney say in a letter published in the Medical Journal of Australia…
More: continued here
Filed under: Gout on June 5th, 2011 | No Comments »